Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Colleague's E-mail is Invalid
Your message has been successfully sent to your colleague.
Benjamin S. Harris, MD, MPH
February 2020, Volume 27, Issue 2; Menopause. 27(2):243-248, February 2020
The risks and benefits of hormone therapy in perimenopausal women have been extensively studied. Less is known about hormone therapy in breast or gynecologic cancer survivors and risk of cancer recurrence. We reviewed the available data to determine whether hormone therapy is safe for breast, ovarian, endometrial, and cervical cancer survivors. We also present a mechanism of reducing breast cancer incidence through estrogen-driven apoptosis pathways, and discuss the role of progestins in the growth of breast cancer stem cells. These concepts are a foundation for future research into the role of hormone replacement in treatment and prevention of breast cancer.